Abstract:There has been a growing trend that activities relating to clinical trials take place at locations other than traditional trial sites (hence decentralized clinical trials or DCTs), some of which are at settings of real-world clinical practice. Although there are numerous benefits of DCTs, this also brings some implications on a number of issues relating to the design, conduct, and analysis of DCTs. The Real-World Evidence Scientific Working Group of the American Statistical Association Biopharmaceutical Section has been reviewing the field of DCTs and provides in this paper considerations for decentralized trials from a statistical perspective. This paper first discusses selected critical decentralized elements that may have statistical implications on the trial and then summarizes regulatory guidance, framework, and initiatives on DCTs. More discussions are presented by focusing on the design (including construction of estimand), implementation, statistical analysis plan (including missing data handling), and reporting of safety events. Some additional considerations (e.g., ethical considerations, technology infrastructure, study oversight, data security and privacy, and regulatory compliance) are also briefly discussed. This paper is intended to provide statistical considerations for decentralized trials of medical products to support regulatory decision-making.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the statistical challenges in the design, implementation, and analysis of decentralized clinical trials (DCTs) in the era of real - world evidence (RWE), and to provide corresponding considerations and suggestions. Specifically, the paper aims to: 1. **Describe selected key decentralized elements**: These elements have a significant impact on the statistical aspects of clinical trials, such as the use of digital health technologies (DHTs), remote data collection, participant screening and recruitment, etc. 2. **Review relevant regulatory guidance documents and frameworks**: Including the guidelines on DCTs issued by the International Conference on Harmonisation (ICH) and other national or regional drug regulatory agencies (such as FDA, EMA, NMPA, etc.). 3. **Discuss statistical considerations**: Covering the statistical challenges and countermeasures in the design, implementation, data analysis, and reporting of DCTs, ensuring that the trial design and data analysis can accurately reflect the research objectives and support regulatory decisions. ### Specific content of the paper #### 1. Introduction Introduces the definition of DCTs and their advantages over traditional clinical trials (TCTs), such as increasing participation, reducing burden, and increasing representativeness. At the same time, it points out the new problems that DCTs may bring, especially in terms of design, implementation, and data analysis. #### 2. Key elements of decentralized clinical trials Discusses in detail several key elements with potential statistical impacts: - **Digital health technologies (DHTs)**: Including wearable devices, mobile applications, etc., for remote data collection and monitoring. - **Participant screening, recruitment, and retention**: Using DHTs for remote identity verification, electronic informed consent, remote follow - up, etc. - **Drug distribution**: How to ensure that drugs are safely delivered to participants and provide clear usage instructions. - **Outcome/endpoint assessment and data collection**: Using DHTs or local healthcare providers (HCPs) for remote assessment. - **Safety monitoring**: Real - time monitoring and timely handling of adverse events through AI and DHTs. - **Data management and monitoring**: Handling a large amount of complex data to ensure the quality and reliability of data. #### 3. Regulatory guidance and frameworks Summarizes the guidance of major global drug regulatory agencies on DCTs, emphasizing the principles and general considerations that should be followed when designing and implementing DCTs. ### Conclusion The paper aims to provide comprehensive statistical considerations for decentralized clinical trials to support the development of medical products and regulatory decisions. By systematically analyzing the key elements of DCTs and the challenges they face, the paper provides a valuable reference for researchers and regulatory agencies.

Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective

Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework

Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges

The value of decentralized clinical trials: Inclusion, accessibility, and innovation

The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data

Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches

The Digital Platform and Its Emerging Role in Decentralized Clinical Trials

The Ethics of Decentralized Clinical Trials and Informed Consent: Taking Technologies' Soft Impacts into Account

Remote Monitoring and Data Collection for Decentralized Clinical Trials

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access

Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative

Linking clinical trial participants to their U.S. real-world data through tokenization: A practical guide

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Recommendations to promote equity, diversity and inclusion in decentralized clinical trials

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

Adoption of Decentralization: Are Our Perceptions Holding Us Back?

Leveraging Decentralized Clinical Trial Management Systems (dCTMS) to Advance Science: Exploring Challenges Related to the Diffusion of Innovation and Its Execution

Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union